Kirin. has filed a patent for a monoclonal antibody that binds to human CCR1, inhibiting its activation by CCL15. The antibody can diagnose CCR1-related diseases like cancer, autoimmune, and inflammatory diseases by detecting CCR1 in biological samples. GlobalData’s report on Kirin gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Kirin Holdings Co Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kirin, Lactobacilli-based drug compositions was a key innovation area identified from patents. Kirin's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Diagnosing ccr1-related diseases using monoclonal antibodies

Source: United States Patent and Trademark Office (USPTO). Credit: Kirin Holdings Co Ltd

A patent application (Publication Number: US20240026017A1) describes a method for diagnosing and treating CCR1-related conditions in humans. The method involves detecting CCR1 in a biological sample using a monoclonal antibody that binds to an extracellular region of human CCR1 and inhibits its activation by CCL15. The monoclonal antibody is selected from a specific list of antibodies with defined amino acid sequences. For diagnosing CCR1-related cancer, autoimmune diseases, or inflammatory diseases, the presence of CCR1 indicates the condition in the subject. In the treatment method, a therapeutically-effective amount of the monoclonal antibody is administered to the subject to treat the CCR1-related condition by inhibiting CCR1 activation.

Furthermore, the patent application specifies the use of genetically recombinant antibodies and various antibody fragments, such as Fab, Fab', (Fab')2, scFv, diabody, dsFv, and peptides comprising CDR, for binding to CCR1. The antibody or antibody fragment can also be conjugated to radioisotopes, low molecular weight drugs, high molecular weight drugs, proteins, or other antibody drugs for targeted therapy. The application lists a range of low molecular weight drugs that can be used in conjunction with the antibody, including chemotherapeutic agents like cisplatin, doxorubicin, and paclitaxel, among others. Additionally, high molecular weight drugs like polyethylene glycol and albumin are also mentioned as potential conjugates for the antibody in treating CCR1-related conditions in humans.

To know more about GlobalData’s detailed insights on Kirin, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.